[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.125.253. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
September 2010

Will Symptomatic Intracerebral Hemorrhages Decrease Among Eligible Dabigatran-Treated Patients Who Receive Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke?—Reply

Author Affiliations

Author Affiliation: Department of Neurology, Rush University Medical Center, Chicago, Illinois.

Arch Neurol. 2010;67(9):1156-1157. doi:10.1001/archneurol.2010.206

In reply

We thank Dr Chan for his observations and comments. The use of chronic anticoagulation is increasing and will likely continue to expand as the population ages. While warfarin is the most widely prescribed oral anticoagulant, the search for oral direct thrombin inhibitors to replace warfarin is attractive for many reasons including ease of monitoring and safety. In the Randomized Evaluation of Long Term Anticoagulant Therapy trial,1 dabigatran was shown to be as effective as warfarin in stroke prevention, with lower risk of major hemorrhage, opening the doors to this therapeutic possibility.

First Page Preview View Large
First page PDF preview
First page PDF preview
×